Table of contents
Varicose veins & co. – what is hidden behind ‚co.‘? Why ‚co.‘ at all? Aren't varicose veins simply a vein or venous valve weakness, an aesthetically and also painfully unpleasant appearance?
What are varicose veins?
Veins transport blood back to the heart. So that the blood doesn't simply flow back against gravity, veins have small Flaps (Venous valvewhich open upwards and close downwards. Blood that has passed through the valve can therefore not go back.
If you have varicose veins (Varicose veinsfail these valves. The blood strains in the vein, the pressure rises, the vein wall gives way, the vein expands and arches visible under the skin, snaking and bluish-purple.
Primary varicose veins are caused by connective tissue weakness or genetic predisposition in about 95ses, which affects offspring with a 45% probability of developing varicose veins if one parent is affected, and a 90% probability if both parents are affected.
Causes and risk factors
The most common reason is so that a Congenital connective tissue weakness. The vein wall is naturally less elastic and stable. This is why varicose veins tend to occur more frequently in families.
Furthermore, factors such as prolonged standing or sitting, obesity, pregnancy (due to increased abdominal pressure), lack of exercise, and age, as connective tissue gradually loses stability and flexibility over a lifetime, are contributing factors.
The often underestimated development
Varicose veins are therefore not purely a cosmetic problem as initially stated. They develop gradually in stages. Most people only notice them late, when the process is already well advanced.
Initially, often only harmless-looking Spider veins, fine, reddish-bluish veins directly under the skin. These are initially only of cosmetic relevance. Over time, visible, widened superficial veins appear, combined with a feeling of heaviness in the legs. This is accompanied by a feeling of tightness and swelling in the evenings. The blood now stagnates to such an extent that fluid leaks out of the vessels into the surrounding tissue.
Without treatment, chronic changes occur, such as brownish-red discoloration of increasingly dry, thus itchy skin, as well as hardening of the tissue, because tissue circulation is permanently impaired.
In the advanced stage, open sores (Leg ulcer). Wounds that do not close on their own due to poor blood circulation. These are very painful and difficult to treat. Likewise, the risk of Phlebitis (Thrombophlebitisbecause the superficial vein becomes inflamed, hard, and painful.
The most dangerous complication is deep vein thrombosis. This is a blood clot that forms in a deep vein of the leg. The life-threatening danger is a Pulmonary embolism, when the clot breaks loose and is swept through the bloodstream into the lungs. There, it blocks blood vessels, which can be fatal within minutes.
What many don't know
Varicose veins are therefore not a cosmetic problem, but a serious one Connective tissue warning sign. People with varicose veins often have weaker connective tissue elsewhere, such as in heart valves, the abdominal cavity (hemorrhoids are anatomically related venous changes), joints, or internal organs.
Varicose veins in the leg are therefore often just the visible part of a systemic connective tissue problem, an expression of an internal process that began much earlier.
With internal bleeding through porous vascular walls, it presents a serious medical picture. The plant-based substances mentioned can supportive act and are always to be seen within the context of a medical evaluation.
Connective tissue weakness - genetic causes
Collagen Genes
COL3A1 Highest Risk
Chromosome 2q31 · Encodes pro-alpha 1(III)-collagen
Mutations in COL3A1 cause vascular Ehlers-Danlos syndrome (vEDS). Type III collagen is a major component of the walls of medium-sized arteries, hollow organs, and skin.
Mutation types and severity
- Glycine nonsense mutations (Gly→X in (Gly-X-Y)ₙ repeat): disrupt triple helix → dominant-negative effect → most severe phenotypes
- Splice site mutations (donor > acceptor): moderate severity
- Null/haploinsufficiency mutations: milder phenotype, longest survival
Molecular mechanism
Mutated collagen III accumulates in the ER → ER stress → activates PLC/IP3/PKC/ERK signaling pathway → uncontrolled smooth muscle cell activation → spontaneous arterial rupture.
Clinical Consequences
Spontaneous arterial dissection/rupture (mainly mesenteric arteries), intestinal and uterine rupture, internal bleeding.
Study Links
- PMC8609142 – vEDS Mechanisms
- PMC6994142 – PLC/ERK Signaling Pathway
- PubMed 36262204 – Arterial Damage
- PubMed 15127738 – vEDS Review
COL1A1 / COL1A2
Chr. 17q21.33 / Chr. 7q22.1 (Chromosome positions: COL1A1 is located on chromosome 17 / COL1A2 on chromosome 7) · Coding pro-alpha1(I) and pro-alpha2(I)
Mutations in COL1A1 and COL1A2 cause Osteogenesis Imperfecta (OI) and classical EDSEhlers-Danlos syndromeType I collagen is the body's most common structural protein (bones, tendons, skin, blood vessels).
Mechanism
Glycine substitutions in the triple helix → structurally unstable fibrils → reduced mechanical resistance. Null mutations → quantitative collagen deficiency (OI type I)Osteogenesis imperfecta)).
Combination effects
Simultaneous COL1A2 + FBN2 mutations cause synergistic ECM dysfunctionExtracellular Matrix – a structure that surrounds and supports cells) with a particularly severe skeletal phenotype (Study 2022).
Study Links
- PMC9270787 – COL1A2+FBN2
- Adv. Rheumatol. 2024 – Review
COL5A1 / COL5A2
Chr. 9q34.3 / Chr. 2q32.2 · Type V collagen
Major genes of classical EDS. Type V collagen regulates the fibril thickness of type I collagen through nucleation control.
Mechanism
Haploinsufficiency in COL5A1 → uncontrolled fibril thickness → dermal and vascular hyperextensibility, atrophic scarring.
NGS panels for classical EDS routinely analyze COL5A1, COL5A2, COL3A1, COL1A1, COL1A2, TNXB, and others.
Study Link
- PMC9164033 - NGS cEDS Panel
Fibrillin System
FBN1 / FBN2 – Microfibrils and TGF-β Regulation
FBN1 Marfan Syndrome
Chr. 15q21.1 · 66 Exons · encodes Fibrillin-1 glycoprotein
Fibrillin-1 is the main component of the 10–14 nm wide extracellular microfibril systems, which serve as a scaffold for elastic fibers and sequester TGF-β in a latent, inactive form in the ECM.
Mutation types
>3,000 pathogenic variants described. Missense mutations in the EGF-like calcium-binding domains → classic Marfan syndrome. Truncating mutations → variable phenotype.
Central mechanism
Defective fibrillin-1 → reduced sequestration of large latent TGF-β complexes (LLCs) via LTBPs → uncontrolled TGF-β release → SMAD2/3 phosphorylation + ERK1/2 activation → pathological aortic remodeling, aneurysm.
Phenotypes
Thoracic aortic aneurysm/dissection (TAAD), ectopia lentis, scoliosis, mitral valve prolapse, dural ectasia.
Study Links
- NCBI GeneReviews – FBN1/Marfan Syndrome
- PMC6639799 – FBN1 Overview
- PubMed 23788295 – TGF-β in MFS
- PubMed 20351703 – Marfan Review
FBN2
Chr. 5q23.3 · Fibrillin-2
FBN2 mutations cause Congenital Contractural Arachnodactyly (CCA), a dominant connective tissue disorder with a Marfan-like appearance.
Mechanism
Fibrillin-2 is particularly active during early embryonic development and regulates BMP signaling. Mutations in exons 24–34 are particularly common.
FBN2 and COL1A2 share the ECM organization pathway; synergistic mutations of both genes produce significantly more severe skeletal phenotypes.
Study Links
- Hum. Genome Var. 2024 – FBN2
- Genetics in Medicine – HDCT
Elastin & Crosslinking
ELN (Elastin)
ELN
Chr. 7q11.23 · Tropoelastin precursor
Elastin is the structural protein of elastic fibers. Tropoelastin monomers are deposited extracellularly on fibrillin microfibrils and cross-linked by lysyl oxidases.
ELN mutations
Heterozygous deletions → Supravalvular aortic stenosis (SVAS). ELN is also part of Williams-Beuren syndrome (7q11.23 deletion). Homozygous ELN null mutations would be lethal.
ECM context
Elastin provides elastic recoil to arterial walls. Fragmentation of elastic lamellae leads to arterial rigidity, aneurysm formation, and venous wall weakness.
Study Link
- Front. Genet. 2022 – Heritable CTD
LOX-Gen family
LOX / LOXL1–4
Chr. 5q23.1 (LOX) · Copper-dependent amino oxidases
Lysyl oxidases initiate covalent cross-linking of collagen and elastin: oxidation of lysine ε-amino groups → aldehydes → spontaneous pyridinoline/desmosine fibrils.
LOX mutations
Loss-of-function variants → familial TAAD. LOX knockout mice die perinatally from aortic rupture with a 60%% reduction in elastin cross-links and a 40%% reduction in collagen cross-links.
Mechanism
Defective cross-linking → structurally unstable elastic lamellae → increased elastase susceptibility → progressive fragmentation → aortic dissection. TGF-β-responsive genes are upregulated in LOX mutants.
LOXL2/L3
In aortic dissection: LOXL2↑ → MMP2↑ → ECM degradation; LOXL3↑ → VSMC proliferation.
Study Links
- PMC4978273 - LOX Mutation TAAD
- Circulation – LOX-Knockout
- PMC8292648 – LOXs in AD
- PubMed 34281165 – LOX Variants
- PMC6693828 – LOX ER-Retention
TGF-β axis
TGFBR1 · TGFBR2 · SMAD2/3 · TGFB2/3 – Loeys-Dietz Syndrome
Central signaling pathway: TGF-β-SMAD axis
TGF-β is sequestered in the ECM in a latent form by LTBPs (latent TGF-β-binding proteins) on fibrillin microfibrils. Defective microfibrils (FBN1 mutations) or direct receptor mutations lead to uncontrolled TGF-β activation:
Latent TGF-β (ECM) → Release → TGFBR2:TGFBR1-Heterodimer → SMAD2/3 Phosphorylation → Nuclear complex with SMAD4 → Gene expression (MMP↑, Collagen↓, Inflammation↑)
Parallel: Non-canonical paths across ERK1/2, p38-MAPK, PI3K/AKT reinforce vascular remodeling.
TGFBR1 / TGFBR2
Chr. 9q22 / Chr. 3p24.1 · TGF-β Receptors I and II
Mutations in TGFBR1 or TGFBR2 cause Loeys-Dietz syndrome (LDS), a TAAD syndrome with bifid uvula, craniofacial features, and pronounced vascular fragility.
Paradox
Despite activating receptor mutations, the downstream TGF-β signaling reinforced (not as expected reduces) – Mechanism: compensatory upregulation of TGFBR1/2 expression.
Study Link
- GeneReviews – LDS Gene
SMAD2 / SMAD3
Chr. 18q21 / Chr. 15q22 · Intracellular signal mediators
Heterozygous loss-of-function mutations in SMAD3 cause Loeys-Dietz syndrome (LDS type 3): aortic aneurysms combined with early-onset osteoarthritis.
SMAD3 mutations show that canonical TGF-β signaling can paradoxically be vasoprotective – its loss leads to uncontrolled ECM degradation.
Study Link
- PMC6639799 – FBN1/TGF-β
ACTA2 / MYH11 / MYLK
Chr. 10q23 / 16p13 / 3q21 · VSMC contractile apparatus
These genes encode vascular smooth muscle cell (VSMC) proteins: α-Smooth-Muscle-Actin (ACTA2), β-Myosin-Heavy-Chain (MYH11), and Myosin-Light-Chain-Kinase (MYLK).
Mechanism
Mutations disrupt VSMC contraction and mechanosensing → secondary ECM remodeling → TAAD. ACTA2 mutations also cause cerebral and coronary artery disease.
Study Link
- PubMed 39064294 - vEDS Management
FOXC2 · VEGFC/VEGFR3 – Varicose Veins & Venous Insufficiency
FOXC2 Varicose Veins
Chr. 16q24.1 · Forkhead transcription factor
FOXC2 encodes a forkhead transcription factor essential for the development and maintenance of venous and lymphatic valves. FOXC2 regulates Delta-like-4 (Dll4), Hey2, and CXCR4 signaling pathways in endothelial cells.
Pathomechanism
FOXC2 loss-of-function mutations → Lymphedema-Distichiasis Syndrome with varicose veins. Twin study (n=2,060 pairs) showed 86%(95%CI: 73–99% ) genetic heritability of varicose veins and linkage to marker D16S520 near FOXC2.
Venous valve failure
In all 18 examined FOXC2 mutation carriers: pathological reflux in the great saphenous vein (vs. 1/12 controls, p<0.0001). 78% also affected in the deep venous system.
Molecular
FOXC2-AS1 (lncRNA) → activates FOXC2-Notch signaling pathway → VSMC phenotypic switch (contractile→synthetic), proliferation, migration → intimal hyperplasia in varicose veins.
Study Links
- PMC1736007 - FOXC2 Twin Study
- Circulation 2007 – FOXC2 Valves
- Biol. Res. – FOXC2-AS1/Notch
- Biomarkers in Medicine – Cardiovascular Disease Review
- NCBI Bookshelf - Pathophysiology VV
MMP-2 / MMP-9 / TIMPs
Matrix metalloproteinases · ECM remodeling
In varicose veins, MMP-2 and MMP-9 are upregulated. MMP-2 activation leads to relaxation of the vein wall → venous dilatation → insufficiency.
Mechanism
Increased hydrostatic pressure → Activation of transcription factor AP-1 → MMP induction → ECM degradation (Collagen III, Elastin↓) → Venous wall weakness. TIMPs control MMP activation as antagonists.
VEGF-A/VEGFR2
Hyperregulation in varicose vein walls explains venous wall permeability and inflammatory symptoms.
Study Links
Biomarkers in Medicine. MMP/TIMP
- PubMed 38980841 – Exom-Seq VV
Clinical phenotypes
Manifestations – An Overview of Genes and Mechanisms
| Phenotype | Primary Genes | Molecular mechanism | Key-signal path |
|---|---|---|---|
| Varicose veins (VV) | FOXC2, NOTCH3, MMP2, MMP9, VEGFA | Valve failure due to FOXC2 loss; MMP-mediated ECM degradation; VSMC phenotype switching | FOXC2→Notch; AP-1→MMP; VEGF-A/VEGFR2 |
| Aortic Aneurysm / TAAD | FBN1, TGFBR1/2, SMAD2/3, ACTA2, MYH11, LOX, COL3A1 | Microfibril dysfunction → TGF-β↑; LOX defect → cross-linking deficit; VSMC contraction loss | TGF-β/SMAD; ERK1/2; PLC/IP3/PKC; LOX/ECM Maturation |
| Internal bleeding / Artery rupture | COL3A1, FBN1, LOX | vEDS: Col-III dysfunction → PLC/ERK hyperactivity → spontaneous media rupture; LOX KO → lack of elastin cross-linking | PLC/IP3/PKC/ERK (vEDS); LOX/Elastin-Crosslinking |
| Cutaneous Hypermobility / EDS | COL5A1, COL5A2, COL3A1, TNXB, ADAMTS2 | Fibril thickness dysregulation; Tenascin-X deficiency → dermal collagen stability↓ | Collagen fibril nucleation; ECM maturation |
| Joint hypermobility | COL5A1, TNXB, FBN1, B3GALT6, B4GALT7 | Dermal/ligamentous ECM instability; GAG biosynthesis disorder (B3GALT6) | ECM structural protein maturation; proteoglycan synthesis |
| Osteogenesis imperfecta (OI) | COL1A1, COL1A2 + 20 more (IFITM5, SERPINF1, ...) | Type I collagen triple helix defects → inferior bone matrix; dominant-negative effect more severe than haploinsufficiency | Collagen I Biosynthesis; ER Stress Response |
| Loose skin | ELN, FBLN4, LTBP4, ATP6V1E1/A | Elastin cross-linking deficit; Fibulin-4 deficiency → Tropoelastin assembly disorder; V-ATPase dysfunction | Elastin Assembly; LOX Maturation; Fibulin-ECM Interaction |
| Marfan syndrome | FBN1 (≥90%); rarely FBN2 | Fibrillin-1 defect → TGF-β overactivation → aortic VSMC dysfunction; ectopia lentis; skeletal overgrowth | FBN1/LTBP/TGF-β/SMAD; Angiotensin-II/AT1R |
Signaling pathways
Molecular Pathways at a Glance
TGF-β / SMAD Canonical Pathway
FBN1 Mutation → LTBP Release → TGF-β Activation → TGFBR2:TGFBR1 → SMAD2/3-P → SMAD4 Complex → Nucleus → MMP↑, Collagen III↓, CTGF↑. Impaired in: Marfan, LDS, vEDS (secondary), Cutis laxa.
2. PLC/IP3/PKC/ERK (vEDS-Weg)
COL3A1 mutation → mutated collagen III in ER → ER stress (if applicable) / reduced wild-type collagen III → ECM defect → unknown mechanosensing → PLC activation → IP3 → PKC → ERK1/2 → VSMC dysfunction → spontaneous aortic rupture. Pharmacologically inhibitable by cobimetinib (MEK/ERK inhibitor) and ruboxistaurin (PKCβ inhibitor).
3. LOX/ECM Cross-linking Pathway
LOX (Copper-Amine Oxidase) → oxidizes lysine residues in collagen/elastin → aldehyde groups → spontaneous desmosine cross-links → mechanically stable ECM. LOX mutation/inhibition → uncrosslinked elastic lamellae → increased susceptibility to proteolysis → aortic dilation. Associated with TGF-β (positively regulated) and MMP2/AKT pathways (via LOXL2).
4. FOXC2-Notch-Venous pathway
FOXC2 (Forkhead Transcription Factor) → regulates Dll4, Hey2, CXCR4 in endothelial cells → venous valve development and maintenance. FOXC2-AS1 (lncRNA) → FOXC2↑ → Notch activation → VSMC phenotype change (SM22α↓, Osteopontin↑) → proliferation/migration → venous intimal hyperplasia, valve failure.
5. MMP/TIMP Balance
Hydrostatic pressure / mechanical stress → AP-1 activation → MMP-2/-9 transcription → Collagen III/elastin cleavage → vein wall loosening / vascular insufficiency. TIMPs (1–4) control MMP activity. Disequilibrium → chronic venous insufficiency, varicose veins, ulcerations. VEGF-A/VEGFR2: activated in parallel.
6. Angiotensin-II / AT1R / ERK (Marfan)
Wall tension + Hypertension → AT1R upregulation → Angiotensin II → TGF-β production↑ (AT1R-dependent) + ERK1/2 activation. Therapeutic: Losartan (AT1R blocker) reduces TGF-β and slows aortic dilation in MFS mouse models and clinical studies.
Gene reference
Other Relevant Genes at a Glance
| Gene | Chromosome | Syndrome / Role | Inheritance |
|---|---|---|---|
| TNXB | 6p21.3 | Tenascin-X deficiency EDS | AR (complete) / AD (haploinsufficiency) |
| ADAMTS2 | 5q35.3 | Procollagen-N-Peptidase; EDS kyphoscoliotic type | AR |
| PLOD1 | 1p36.2 | Lysyl hydroxylase; Hydroxylysyl-pyridinoline cross-linking; kEDS | AR |
| NOTCH1/3 | 9q34.3 / 19p13 | NOTCH3: CADASIL; NOTCH1: Aortic valve disease; venous dysfunction | AD |
| PRKG1 | 10q11.2 | cGMP-dependent protein kinase I; TAAD; VSMC relaxation defect | AD |
| BGN | Xq28 | Biglycan (proteoglycan); X-linked TAAD; TGF-β sequestration | X-linked |
| FLNA | Xq28 | Filamin A; periventricular nodular heterotopia; aortic pathology | X-linked dominant. |
| SLC2A10 | 20q13.1 | GLUT10; Arterial Tortuosity Syndrome; TGF-β modulation | AR |
| LTBP4 | 19q13.2 | Latent TGF-beta binding protein; cutis laxa type IB | AR |
| FBLN4/5 | 11q13 / 14q32.1 | Fibulin-4/-5; Elastin fiber assembly, Cutis laxa | AR |
All information is based on peer-reviewed primary literature. (As of: 2024)
Clinical decisions require human genetic counseling.
Genetic findings must always be interpreted in a clinical context.
Epigenetics
DNA Methylation in Marfan Syndrome (EWAS)
The first epigenome-wide association study (EWAS) in MFS patients was performed using the Illumina 450k DNA methylation array on stored peripheral whole blood samples from 190 MFS patients from the COMPARE trial. Twenty-eight differentially methylated positions (DMPs) were significantly associated with aortic diameters, 7 of which were in genes previously associated with cardiovascular diseases (HDAC4, IGF2BP3, CASZ1, SDK1, PCDHGA1, DIO3, PTPRN2). A DMR cluster on chromosome 5 involved a large family of protocadherins (PCDH), which had not previously been described in MFS. PubMed Central → PMC8665617
FBN1 promoter methylation
Differential methylation and expression of genes related to inflammation (e.g., IL-10, IL-17) and oxidative stress (e.g., PON2, TP53INP1) have been linked to aortic pathology in MFS. The TGF-β signaling pathway plays a pivotal role in MFS pathology, with aberrant methylation of related genes potentially increasing active TGF-β levels and exacerbating aortic lesions. PubMed Central → PMC12074684
Histone modifications
EZH2 (H3K27-Methyltransferase) represses SM22α in Fbn1C1039G/+ mouse models → VSMC phenotypic switch → aortic disease. Increased H3 acetylation and methylation in the media of TAA tissue (FBN1 and TGFBR2 mutations) correlates with SMAD2 overexpression – an epigenetic memory of pathological remodeling.
Diagnostics
Color Doppler ultrasonography
- Identification of insufficient perforating veins
- Determination of the proximal and distal insufficiency points (critical for surgical extent)
- Exclusion of deep vein thrombosis
Photoplethysmography (PPG)
To quantify venous pump function (which, according to guidelines, cannot solely justify surgery).
The Venous Clinical Severity Score (VCSS) and quality of life instruments such as AVVQ or CIVIQ objectify the burden of complaints for study purposes and individual therapy decisions.
Therapy (according to guidelines)
Endovenous thermal ablation (EVT)
The current S2k guideline (AWMF 037-018) and international guidelines recommend for symptomatic great saphenous vein insufficiency Endovenous thermal procedures before surgical procedures or foam sclerotherapy. Mechanism: Laser energy or radiofrequency (VNUS procedure) generates thermal denaturation of the vein wall from the inside → fibrosis → permanent closure.
A retrospective study published in 2025 (n=300, Alwahbi 2025) confirmed that endovenous laser ablation ambulatory under tumescent local anesthesia can be carried out safely and effectively – an important step towards reducing perioperative effort.
Radially emitting laser fibers (as in the ELVeS-Radial system) show similar closure rates compared to older bare-tip fibers, with a tendency towards less pain and bruising.
Surgical stripping (crossectomy + Babcock stripping)
Contrary to a common misconception, the classic stripping procedure consistently shows in studies low recurrence rates and is further indicated in pronounced truncal varicosis with large vein diameter or in cases of contraindication for endovenous procedures. The disadvantages are open access and the risk of transient cutaneous nerve damage.
Sclerotherapy
Method of choice for Recurrent varicose veins and in older, multimorbid patients. Sclerotherapy creates localized vascular wall damage (chemical), leading to obliteration and fibrosis. In saphenous vein varicosis, the recurrence rate is significantly higher than with thermal procedures, therefore it is only an alternative, not a primary procedure for the Great saphenous vein. For spider veins and reticular veins is she against it the method of choice.
Venous glue (N-butyl-2-cyanoacrylate)
Closure of the vein using tissue adhesive. The advantage is that no tumescent anesthetic is necessary and no compression dressing is required. A disadvantage is the high cost. There is currently less long-term data available compared to established procedures.
Conservative therapy
According to the guideline, conservative therapy is in every stage possible and sensible, even after invasive procedures as adjuvant therapy.
Compression therapy (medical compression stocking classes I-III) reduces ambulatory venous pressure and has proven effects on edema, skin changes, and ulcer healing.
In the long term, consistent compression therapy significantly reduces quality of life, which often justifies the invasive procedure.
Pharmacotherapy
Celiprolol for vEDS (COL3A1 mutations)
Mechanism of action
Celiprolol is a dual β1-antagonist with β2-agonistic vasodilatory properties, which exerts mechanical stress on collagen fibers PubMed Centralin the vessel wall is reduced and its load-bearing capacity is increased. Recent studies also provide evidence of an influence on TGF-β expression and β-adrenergic activity. Bisoprolol (purely β₁-selective) shows no improvement in aortic biomechanics in the vEDS mouse model – the β₂ component is pharmacologically essential.
Key studies:
- BBEST-RCT (Lancet 2010): n=53; 5 years of treatment. Primary endpoints (arterial rupture/dissection): 5/25 (20%) on Celiprolol vs. 14/28 (50%) control; HR 0.36 (95%CI 0.15–0.88; p=0.040). Study stopped early due to treatment benefit. Dosage: 200–400 mg/day (twice daily). PubMed → PubMed 20825986
- Real-World (Brescia, 12 years old): Trotz 80% der Patienten auf Maximaldosis blieb das jährliche Risiko symptomatischer vaskulärer Ereignisse bei 8,8% – das Risiko bleibt unter Celiprolol erheblich. Sage Journals → Vasc. Med. 2024
- Irbesartan-Add-on-RCT (Circulation 2024): Multicenter RCT of Irbesartan (AT1R blocker) in addition to Celiprolol - ongoing. Circulation 2024
- Systematic Review 2025 (n=323): Celiprolol appears to be a promising treatment for reducing vascular events in vEDS and could significantly lower morbidity and mortality. Future research should refine treatment protocols and further elucidate mechanisms of action. PubMed → PMC12195525
Losartan / AT1R blocker for Marfan syndrome
Mechanism: FBN1 mutation → defective fibrillin microfibrils → uncontrolled TGF-β release → AT1R upregulation by wall stretch + hypertension → enhanced TGF-β increase (positive feedback). Losartan blocks AT1R → reduces TGF-β production → slowed aortic dilation rate. Genotype effect: Haploinsufficiency mutations benefit more than dominant-negative. Important: In the vEDS mouse model, losartan does not affect aortic mechanics – different pathomechanisms.
Experimental substances against PLC/PKC/ERK (vEDS):
| Substance | Attack point | status |
| Cobimetinib (MEK Inhibitor) | ERK1/2; FDA-approved for melanoma | Preclinical in vEDS; prevents aortic rupture in Col3a1G209S/+- mice |
| Ruboxistaurin | PKCβ Inhibitor | Preclinical; significantly improved survival rate in mouse models |
| Hydralazine | IP3-Ca²⁺, PKCβ; FDA-approved (hypertension) | Preclinical; combinable with ERK/PKC inhibitors |
| Enzastaurin | PKCβ Inhibitor | Clinical Phase I/II (NCT05463679; currently suspended) |
| Antiandrogen | Androgen/Oxytocin→PKC/ERK; explains pregnancy risk | Preclinical |
Sources: PMC6994142, PubMed 39064294, PMC8609142
Gene therapy pipeline
Basic principle
Dominant-negative mutations (a mutated allele sabotages the wild-type protein) require either selective elimination of the mutated allele or precise correction. In the case of haploinsufficiency, upregulation of the wild-type allele may be sufficient.
| Approach | Targeted disease | Mechanism | status |
| CRISPR/Cas9 HDR | vEDS (COL3A1), MFS (FBN1) | Homologous recombination + donor template | Preclinical (iPSC models) |
| Base-Editing (ABE/CBE) | vEDS, OI (COL1A1/2) | Point mutation correction without double-strand break | Preclinical |
| ASO-Exon-Skipping | vEDS (COL3A1 Exon 10/15) | Splice Modulation; Elimination of Mutated Protein | Preclinical (patient fibroblasts) |
| Allele-specific siRNA | vEDS (dominant-negative) | RISC reduction of mutated alleles; conversion DN→haploinsufficiency | Preclinical (fibroblast model) |
| AAV gene replacement | OI (COL1A1), EDS | AAV-Delivery of functional copies | Preclinical/early Phase I |
ASO-Exon Skipping (IJMS 2024)
Antisense oligonucleotides designed to redirect COL3A1 pre-mRNA splicing and exclude exon 10 or 15 were transfected into dermal fibroblasts from vEDS patients. Efficient exon skipping was achieved, and intracellular collagen III expression was increased after ASO treatment; however, collagen III deposition into the extracellular matrix was reduced in patient cells. PubMed The exon 10-encoded glycosylation signal and the exon 15-encoded hydroxylysine triplets are essential for homotrimer assembly. PubMed 39201504
Allele-specific siRNA
The best discriminatory siRNA with the mutation at position 10 achieved >90% silencing of the mutated allele without affecting the wild-type allele. After siRNA treatment, collagen fibrils were similar to those of normal fibroblasts. Furthermore, it was shown that the expression of mutated COL3A1 activates the unfolded protein response and that the reduction of the mutated protein by siRNA reduces cellular stress. PubMed Central → PMC3290443
Molecular Biology and Therapeutic Potential
GJD3 / Connexin Pharmacology
Molecular Basis of GJD3 (Gap Junction Protein Delta 3)
GJD3 encodes Connexin 31.9 (Cx31.9), a member of the 21-member connexin protein family in humans. GJD3 encodes a member of the large family of connexins, which are membrane proteins that form intercellular channels and gap junctions, enabling the transport of low-molecular-weight substances between cells, and have been shown to play important roles in inflammation, wound healing, and thrombosis. PubMed Central
Structural principle
Six connexin monomers form a connexon (hemichannel) on the cell surface. A connexon interacts with a connexon of an adjacent cell → complete gap junction channel. GJD3 belongs to the delta subfamily of connexins; its closest paralog is GJA3 (Cx46). Known interacting proteins: TJP1 (Tight Junction Protein 1, ZO-1) – important for the regulation of gap junction permeability.
The protective GJD3-p.Pro59Thr polymorphism
A missense variant (rs201955556-T; PIP=0.45) in the single exon of GJD3 was associated with a lower risk of varicose veins (OR=0.62 [0.55–0.70]; P=1.0×10⁻¹⁴). The absence of pleiotropy in a phenom-wide analysis and its membership in the connexin gene family highlight GJD3 as a potentially connexin-modulating therapeutic strategy for varicose veins. PubMed Central
The variant is exclusively associated with a lower risk for varicose vein endpoints, suggesting a highly specific etiopathology of GJD3 on varicose veins. Nature Important: In a genome-wide analysis of >1,700 disease endpoints in the FinnGen R5 data, GJD3 shows no pleiotropy for other diseases—a rare feature that underscores therapeutic specificity.
The variant is enriched 56-fold in Finns compared to non-Finnish Europeans, demonstrating the discovery power of isolated populations. In UK Biobank exome data (n=281,852), a consistent, albeit not significant, association is observed between GJD3 missense burden and reduced rates of varicose vein surgery.
Further GJD3 associations: Missense variants in GJD3 are associated with lower SHBG (Sex Hormone-Binding Globulin) levels and lower platelet distribution width (PDW) – both potential mechanisms involving hormonal regulation of venous wall integrity.
Connexin Pharmacology
Therapeutic approaches
Connexins are pharmacologically promising targets, as gap junction channels can be modulated by several mechanisms:
| Approach | Mechanism | Examples |
|---|---|---|
| Gap junction blocker | Inhibit intercellular communication; reduce inflammatory signal spread | Carbenoxolone, Mefloquine (experimental) |
| Connexin Mimetic (Peptide) | Binding to specific connexin domains; modifying channel opening | Gap26, Gap27 (Connexin-43 Peptide) |
| Hemichannel Modulators | Selective inhibition of uncontrolled ATP/inflammatory mediator release | Tonabersat (clinically tested for epilepsy) |
| CRISPR/Cas9-Knockout/-Knockin | Direct GJD3 Modification to Validate the Therapeutic Concept | Preclinical |
| Sirolimus/mTOR | Indirect Connexin Expression Modulation | Experimental |
The exact function of GJD3/Cx31.9 in venous endothelial and smooth muscle cells has not yet been fully elucidated. It is known that Cx43 (GJA1), a related connexin, plays important roles in VSMC proliferation, inflammation, and wound healing in vascular tissues; analogous functions for GJD3 are hypothetical but mechanistically plausible. The association with platelet distribution width (PDW) suggests possible platelet functions.
Important note: GJD3 p.Pro59Thr is a loss-of-function-nearby missense variant (Pro→Thr at position 59 of the single exon) – the protective allele is the rare T allele. This implies that pharmacological inhibition von GJD3 could theoretically reduce the risk of varicose veins. PMC9849365
CRISPR Base Editing in Collagen Genes
Protocols and Results
Why Base Editing is Particularly Suitable
Classical CRISPR/Cas9 generates double-strand breaks (DSBs) that lead to indels via error-prone NHEJ repair – problematic for collagen genes, where small frameshifts can generate catastrophic dominant-negative proteins. Base Editors (BE) catalyze direct chemical base conversions without DSB:
- Adenine Base Editors (ABE8e, ABE7.10): A→G conversion (on the sense strand: T→C on the antisense strand)
- Cytosine Base Editors (CBE4max, BE4max): C→T Conversion
COL1A1 Promoter Base Editing
Adenine base editing (ABE), a cutting-edge gene editing technology that enables precise base conversions without inducing double-strand DNA breaks, was employed for the targeted suppression of COL1A1 expression. ABE8e was utilized to target the CCAAT box of the Col1a1 promoter. A 20-nucleotide protospacer was designed to leverage an optimal NGG PAM for S. pyogenes Cas9. The editing efficiency in fibroblasts was 18%. PubMed Central
The CCAAT→CCGGA mutation disrupts CBF transcription factor binding → inhibits RNA polymerase II initiation → reduced collagen production without compensatory upregulation in neighboring wild-type fibroblasts. → PMC11989027
CRISPR/Cas9 HDR at COL1A1 (Osteogenesis Imperfecta) – iPSC Strategy
CRISPR/Cas9 correction of the COL1A1 gene in OI-iPSCs rescued the reduced type I collagen expression in osteoblasts differentiated from OI-iPSCs. The osteogenic potential was restored by gene correction. This study suggests a new treatment option and in vitro disease modeling using patient-derived iPSCs and CRISPR/Cas9 gene editing. PubMed → PMC8307903
AAV-delivered CRISPR-Cas9 for COL1A2 in vivo (Mol. Ther. Nucleic Acids 2024)
Since OI is often caused by single nucleotide mutations in COL1A1 or COL1A2, a genome editing strategy was developed to correct a Col1a2 mutation in an OI mouse model. Using a recombinant adeno-associated virus (rAAV), CRISPR-Cas9 was delivered to bone-forming osteoblast lineages of the skeleton. HDR-mediated genome editing was enhanced when CRISPR-Cas9 was combined with a donor AAV vector. This approach effectively reversed osteogenic differentiation dysregulation and reduced bone matrix turnover rates in OI mice after systemic administration. PubMed → PMC10797194
Review: Gene-Editing for Collagen Disorders (Gene Therapy 2025)
Gene-editing technologies, particularly CRISPR-Cas systems, have emerged as promising therapeutic options for collagen disorders and represent a potential one-size-fits-all solution. This review provides an overview of current gene-editing strategies for collagen-related diseases, including osteogenesis imperfecta, Alport syndrome, and others. Nature → Nature Gene Therapy 2025
Technology Comparison: Gene Therapy Modalities for Collagen Genes
| Technology | Advantage | Limitation | Optimal indication |
|---|---|---|---|
| CRISPR/Cas9 + HDR | Precise, universal | DSB risk, low efficiency in post-mitotic cells | iPSC correction ex vivo |
| Base Editor (ABE8e) | No delay, high precision | PAM dependence, only transitions (A→G, C→T) | Point mutations in promoters/exons |
| Prime Editing | Flexible (all 12 base changes), no self-winding mechanism | Lower efficiency, larger constructs | Insertions/Deletions/all SNVs |
| ASO-Exon-Skipping | RNA level, reversible | Post-translational modification often essential | Selected in-frame mutations |
| Allele-specific siRNA | >90% Allele Specificity | Mutation-specific, each needs its own siRNA | Dominant-negative Mutations |
| AAV gene replacement | In-vivo capable, clinically most advanced platform | Immunogenicity, insert capacity (4.7 kb), integration mosaic | Haploinsufficiency disorders |
Polygenic risk scores
Clinical Risk Stratification
Concept and Fundamentals of the Polygenic Risk Score (PRS)
A PRS sums weighted effect allele doses across thousands to millions of GWAS-associated SNPs: PRS = Σ(β_i × Genotype_i). In contrast to monogenic diagnostics (rare variants with large effects), the PRS captures cumulative effects of common variants with small individual effects.
PRS for abdominal aortic aneurysm (AAA)
Given that the heritability of abdominal aortic aneurysm is high (possibly up to 70%) and AAA GWAS have identified numerous associated variants, there is interest in whether genetic information can supplement population-based screening strategies. A PRS has been developed that leverages pleiotropy with related conditions. Compared to the lowest PRS tertile, the middle and highest tertiles have hazard ratios for AAA of 2.13 (95%CI 1.61–2.82) and 3.70 (95%CI 2.86–4.80). PubMed Central
Simulation Modeling Shows: PRS-Stratified Screening Could Screen High-Risk Male Patients Earlier (Before Age 65) and Include High/Intermediate PRS Female Smokers for the First Time – a Revolution Compared to the Current UK Standard (Men >65 Years Only). PMC11401842
PRS for Varicose Veins: Clinical Validation
A polygenic risk score (PRS) was derived in an independent cohort (FinnGen, n=17,027 varicose vein cases and 190,028 controls). Its predictive utility and correlation with varicose vein surgery was demonstrated. PubMed Central
Patients in the upper PRS deciles have a significantly higher likelihood of undergoing varicose vein surgery – thus, PRS correlates with clinical severity, not just disease incidence. This opens the door for genetically informed treatment intensification.
PRS in Marfan Syndrome: Modifying Genetic Factors
Marfan syndrome, although monogenic (FBN1), exhibits significant phenotypic variability despite the same mutation. Current research is investigating whether an additive polygenic score (modifier genes, ECE1, PRKG1, MMP cluster) can improve cardiovascular risk stratification.
- Aortic diameter is not reliably predicted by extracardiac phenotypes: The severity of cardiac manifestations in Marfan syndrome was independent of extracardiac phenotypes and the aggregated extracardiac score. The severity of extracardiac involvement did not appear to be a useful clinical marker for cardiovascular risk stratification. PubMed Central
- This underscores the need for genetic modifiers and biomarkers (MFAP4, desmosine, TGF-β levels) for individual risk prognosis.
Aortic Aneurysm: Polygenic Susceptibility and Sac Size
For rare diseases like Marfan syndrome or Ehlers-Danlos syndrome, the clinical utility of genetic testing is proven and applied, but for more common complex diseases like AAA, the interpretation and translation of large-scale genetic studies are challenging at best. A previous study using a genetic risk score derived from 4 variants showed that a high GRS was associated with aneurysm growth rate independently of baseline size. Nature
Clinical Implementation: Where does PRS-guided risk stratification stand?
Polygenic risk scores (PRS) have demonstrated predictive validity across a range of cohorts and diseases, but quantifying their clinical utility remains challenging. As PRS can be derived from a single biological sample and remains stable throughout life, there is potential to leverage PRS to optimize existing screening programs. High-risk individuals (PRS OR>2) and very high-risk individuals (PRS OR>3) have been identified, and optimal screening ages for these genetically high-risk individuals have been estimated. Nature
Challenges in Clinical Translation:
- European PRS Bias: Most GWAS are in populations of European ancestry; multi-ancestry PRS perform better in diverse populations, but not yet optimally
- Explained Variance: VV-PRS currently explains only ~2-5% of the phenotypic variance → much heritability still unexplained (Dark Heritability)
- Integration with clinical risk factors: PRS + BMI + Age + Medical history > any factor alone
- Regulatory Approval: No PRS has yet been approved by the EMA/FDA for clinical indication in connective tissue diseases
Loeys-Dietz syndrome
Genotype-Phenotype in Detail
Among 103 patients from 60 families with LDS 1–5 (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3), 77 aneurysms were identified in 43 patients. 75% of the aneurysms were located in the arch vessels or cerebral circulation. The median age at AA diagnosis was 40 years. American College of Cardiology These data show: LDS patients have a significantly higher risk of peripheral and cerebral Aneurysms in Marfan Patients - A Critical Distinction for Surveillance Protocol.
Complete Source Overview
| Topic | Direct link |
|---|---|
| GJD3/Connexin Study (FinnGen GWAS) | PMC9849365 |
| Connexin Structure & Pharmacology (Biology 2024) | PubMed 38785780 |
| GJD3 haplotype in familial Meniere's disease | Genome Medicine 2025 |
| Gene Editing Collagen Disorders Review (Gene Therapy 2025) | Nature Gene Therapy |
| ABE8e: COL1A1 Promoter Base Editing (IJMS 2025) | PMC11989027 |
| AAV+CRISPR COL1A2 in vivo (Mol. Ther. Nucleic Acids 2024) | PMC10797194 |
| CRISPR COL1A1 Correction in OI-iPSCs (JCM 2021) | PMC8307903 |
| CRISPR + PNA in dominant COL1A1 double mutation | JBMR 2023 |
| PRS for aortic aneurysm + screening modeling | PMC11401842 |
| PRS Potential for Premature Mortality Prevention | Nature Communications 2026 |
| Extracardiac phenotypes do not equal cardiac risk in Marfan syndrome. | PMC10942553 |
| LDS: Aortic Aneurysms 103-Patient Cohort | ACC.org |
| GWAS VV – 810,625 individuals (Nat. Commun. 2022) | PMC9163161 |
| Multi-ancestry GWAS VV – 139 Loci (Nat. CVR 2023) | PubMed 39196206 |
| BBEST-RCT Celiprolol (Lancet 2010) | PubMed 20825986 |
| Systematic Review Celiprolol 2025 | PMC12195525 |
| PLC/ERK signaling pathway vEDS (JCI 2020) | PMC6994142 |
| ASO Exon-Skipping COL3A1 (IJMS 2024) | PubMed 39201504 |
| Allele-specific siRNA vEDS | PMC3290443 |
| EWAS Marfan Syndrome (Clin. Epigenetics 2021) | PMC8665617 |
| DNA Methylation MFS Aorta (PMC 2025) | PMC12074684 |
| LOX-Knockout Aortic Rupture (Circulation) | AHA Journals |
| COL3A1 Mechanisms of vEDS – 4 Decades | PMC8609142 |
| FBN1 Gene and TGF-β (PMC 2019) | PMC6639799 |
| GeneReviews FBN1/Marfan | NCBI NBK1335 |
| FOXC2 Valve Failure (Circulation 2007) | AHA Journals |
State of the Art 2026
What is proven
Over 200 monogenic disease genes are involved in connective tissue weakness. The mechanisms converge on five central axes: TGF-β/SMAD signaling, PLC/PKC/ERK activation, ECM cross-linking deficits (LOX), transcriptional control of vascular identity (FOXC2), and MMP-mediated matrix degradation.
What is in development
CRISPR base editing shows proof-of-concept for COL1A1/COL1A2 in iPSC systems; AAV-mediated gene correction works in mouse models for OI; ASO strategies currently fail due to the post-translational collagen assembly problem; allele-specific siRNA achieves >90% allele specificity in patient fibroblasts.
What remains unclear
The precise mechanism by which reduced ECM collagen III activates the PLC/IP3/PKC/ERK pathway is not mechanistically understood; how GJD3/Cx31.9 influences venous wall integrity has not yet been functionally characterized; whether PRS-assisted layering leads to better clinical decisions in connective tissue diseases has not yet been demonstrated in studies.
Plant-based active ingredients for vascular walls & connective tissue
OPC – Oligomeric Proanthocyanidins (highest evidence)
Sources: Grape seed extract, pine bark extract (Pycnogenol), red grape skin, blueberries
OPC is able to directly strengthen the capillary walls by attaching itself to protein structures (collagen and elastin). This keeps the vessel walls strong, soft, and supple. Within 24 hours, the resistance of the vessel walls nearly doubled in studies.
Especially relevant: OPC directly helps with hemorrhages and internal bleeding due to permeable vessels. This condition manifests, for example, as bloody capillaries in the eyes, immediate bruising from the slightest bump, burst blood vessels, or pinpoint bleeding under the skin.
OPC protects the collagen structures of the vessel walls, thereby counteracting excessive permeability of the vessel walls.
In combination with vitamin C, it is considered particularly effective: When OPC is administered together with vitamin C, fine cracks in blood vessel walls can be repaired.
Studies
Mechanism - Vascular Permeability OPCs are proven to inhibit lipid peroxidation, platelet aggregation, and capillary permeability and fragility, and they affect enzyme systems such as phospholipase A2, cyclooxygenase, and lipoxygenase.
Study Link
- 10767669
Mechanism – Collagen & Vascular Wall Structure: OPCs act as natural collagen crosslinkers and prevent the proteolytic degradation of collagen types I and III by metalloproteinases, contributing to the stability of vascular walls.
Study Link
- 37097399
Experimental Proof – Capillary Permeability: In an animal model (collagenase-induced vascular permeability), it was shown that pretreatment with procyanidolic oligomers (PCO) significantly prevented the increased capillary permeability in brain capillaries, aorta, and myocardial capillaries.
Study Link
- PubMed PMID 2165237
Internal bleeding / hemorrhages – directly relevant: OPCs complex proteins and inhibit enzymes involved in the degradation of vascular tissue. This protein-binding action protects the structural integrity of arteries and veins.
Study Link
Alt Med Review – Full Text PDF
Study data on dosage
In clinical studies, doses between 50 and 300 mg daily have been used. For general antioxidant protection, 50 mg/day is recommended; 100 mg/day (2x 50 mg) can strengthen capillaries; symptoms of chronic venous insufficiency were alleviated from 150 mg/day.
Study Link
- EBSCO Research Starters
Specifically for capillary bleeding and venous insufficiency: In a clinical study with 24 patients with uncomplicated chronic venous insufficiency, 100 mg of OPC/day were administered orally. Over 80 % of the patients showed a positive clinical response – significant symptom improvement was already noticeable after the first 10 days of treatment. No side effects were reported.
Study Link
- 10356940
In a double-blind study with 50 patients with varicose veins, 150 mg/day of grape seed OPC was more effective in reducing symptoms than the bioflavonoid diosmin. Another double-blind, placebo-controlled study with 71 subjects found significant improvement in severity, swelling, and leg discomfort with 100 mg three times a day (= 300 mg/day) – in 75 % of the OPC group within one month.
Study Link
- OPC Reference Guide – Source-Based
Summary of OPC Dosage Levels:
| Goal | Dose/Day | Course foundation |
|---|---|---|
| Prevention / Antioxidant | 50–100 mg | General Consensus Data |
| Capillary reinforcement | 100 milligrams | PMID 10356940 |
| Venous insufficiency, edema | 150–300 mg | Multiple RCTs |
| Acute Phase / Therapeutic | 300–500 mg | Clinical experience |
Sources / Preparations
Purchase criteria
- Actual OPC content (not just „polyphenols“ or „grape seed extract“) must be declared
- The measurement method should be the Masquelier HPLC method or the vanillin method.
- Raw material preferably from France (highest natural OPC content)
- Do not take with protein sources (milk) - reduces absorption
Preparations
ANTHOGENOL® MASQUELIER’s® Original OPCs Capsules
The only OPC preparation that is exactly based on the Masquelier original extract tested in clinical studies.
- Contents: 100 mg Masquelier’s® Original OPCs per 2 capsules (75 % Vitis vinifera, 25 % Maritime pine)
- The taxifolin from pine bark complements the spectrum of grape seed OPC to a complete proanthocyanidin profile
- Available in Germany, Austria, Switzerland through pharmacies and online pharmacies (e.g., Shop Apotheke, bio-apo.com)
- Price: approx. €48–€55 / 90 capsules (= approx. 45 days at 2 capsules/day)
- Also as Drops available (for people with swallowing difficulties)
Medverita OPC 95% Grape Seed Extract
- 300 mg Extract / Capsule, standardized to 95 % OPC = ~285 mg pure OPC / Capsule
- Clear declaration, no unnecessary fillers
- Suitable for therapeutic dosages (150–300 mg OPC/day)
Echt Vital OPC – French Grape Seed Extract
- ≥200 mg pure OPC / capsule, 95% % polyphenol content
- Pure French raw material, no additives, vegan
- In Germany, processes
For the clinical outcome (vessel walls, capillary bleeding): ANTHOGENOL® offers the best proof through proximity to studies. For purely high-dose OPC supply, Medverita 95 % is better (cheaper, higher dose per capsule).
OPC products must be subject to Masquelier-Method Standardized to show the actual OPC content (not just total polyphenols). The pure OPC content in the extract should be ~40 %.
OPC should not without medical consultation along with blood thinners (e.g., Marcumar, Aspirin) are taken.
Horse chestnut (Aesculus hippocastanum)
Active ingredient: Aescin
Aescin improves blood circulation through the veins and seals damaged vessel walls, reducing the leakage of fluid from the veins into the tissue. This diminishes the formation of edema and allows existing edema to recede.
The active ingredients in horse chestnut strengthen blood vessel walls and can therefore prevent excessive bruising. Preventive use can be particularly useful for people who tend to bruise easily.
Studies
Cochrane Review (highest level of evidence): 17 randomized controlled trials were included in the Cochrane review. In all studies, the extract was standardized to aescin – the main active ingredient in horse chestnut seed extract. The studies showed an improvement in leg pain, swelling, and itching.
Study Link
- Cochrane PMC 7144685
Mechanism of action – Vascular sealing: Aescin likely works by „sealing“ leaky capillaries, improving the elastic strength of veins, preventing the release of vessel-damaging enzymes, and blocking physiological events that lead to vein damage.
Study Link
- PMC 3833478
Molecular Mechanism (In vitro): In in-vitro studies, aescin inhibited hyaluronidase activity by 93 %, reducing the permeability and plasma loss from vascular wall endothelial cells, thereby preventing edema formation. Aescin shifts the balance between proteoglycan synthesis and degradation in favor of synthesis.
Study Link
- ScienceDirect – Brazilian Journal of Pharmacognosy
Meta-Analysis (13 RCTs, 1,051 patients): A systematic literature review identified 13 RCTs (1,051 patients) and 3 observational studies (10,725 patients). Leg volume, ankle and calf circumference, edema, pain, tightness, swelling, and itching were examined.
Cochrane-validated study data on dosage
The most common clinically tested dosage of horse chestnut seed extract (HCSE) is 300 mg HCSE twice daily, standardized to 50 mg aescin per dose – corresponding to a Total daily dose of 100 mg aescin.
Study Link
- PMC Cochrane Summary 3833478
Key reference study (Lancet 1996):
The key study by Diehm et al. (1996, Lancet) used exactly this dosage (50 mg aescin twice daily = 100 mg/day) for 12 weeks with 240 CVI patients and showed results comparable to compression therapy.
Study Link
- PubMed Systematic Review PMID 12518108
Dosage Table Aescin:
| Application | Dose of HCSE/Day | Dose of aescin/day | Duration |
|---|---|---|---|
| Therapeutic (CVI, Edema) | 600 mg (2 x 300 mg) | 100 milligrams | 8–12 weeks |
| Maintenance dose | 300-450 mg | 50–75 mg | Long term |
| Postoperative (swelling) | 20–40 mg Aescin | direct | short-term |
Use escin-free, standardized extracts (16–20 % aescin). Do not use for kidney or liver diseases. Note interactions with anticoagulants.
Sources / Preparations
Horse chestnut extract is available in Germany as an authorized medicine available – this is an important quality advantage over dietary supplements, as efficacy and standardization are subject to regulatory review.
Purchase criteria
- At least 100 mg Aescin/Tag (Cochrane-validated minimum dose)
- Extraction with alcohol (not just water - aescin is hardly soluble in water!)
- Standardization to 16-20 % Aescin
- Prefer sustained-release (more even release)
- Esculin-free – the contained toxin must have been removed
Preparations (all authorized medicines)
Venostasin® retard 50 mg – Klinge Pharma
- The reference product used in the majority of clinical trials
- 50 mg aescin / capsule (retarded), 2 capsules/day = 100 mg Aescin/Tag
- Prescription medicine, available only in pharmacies
- Available from, among others, Shop Apotheke, DocMorris, and any local pharmacy
- Price: approx. €15–20 / 50 capsules
Aesculaforce® forte Venen – A.Vogel (also Switzerland)
- 50 mg Aescin / Film-coated tablet from fresh horse chestnut seeds (fresh plant extract)
- 2 tablets/day = 100 mg aescin/day
- Medicinal product authorized according to phytotherapy standards
Aescuven® forte – Cesra
- Standardized dry extract, standardized to Aescin
- Approved Drug, Prescription Only
Venostasin® XR – best-documented preparation, directly used in clinical trials, regulatorily approved, cost-effective.
Red vine leaf (Vitis vinifera)
Active ingredients Flavonoids, Quercetin, OPC
Red vine leaf protects capillaries and has antioxidant effects. It is one of the classic phytotherapeutic remedies for venous insufficiency and connective tissue weakness.
Pine bark extract (Pycnogenol®)
Active ingredients Proanthocyanidins, Bioflavonoids
Pine bark extract strengthens collagen structures and, like grape seed extract, contains highly concentrated OPC. It is considered particularly bioavailable and is a good alternative for people with grape intolerance.
Reishi mushroom (Ganoderma lucidum)
Active ingredients Triterpene, Beta-Glucan
Reishi triterpenes lower blood pressure and strengthen the cardiovascular system. As radical scavengers, age-related damage to the heart, liver, and kidneys can be reduced, as can arteriosclerotic vascular constrictions.
Reishi has an indirect vascular-protective effect due to its strong antioxidant and anti-inflammatory properties – it protects the vascular endothelium from oxidative stress.
Studies
Cardiovascular Effects – Cochrane/Review: Multiple in vitro studies and animal models have shown antioxidant, antihypertensive, lipid-lowering, and anti-inflammatory properties of G. lucidum. However, evidence from clinical studies is inconsistent, partly due to different formulations.
Active Ingredients and Mechanisms The pharmacologically most important components of G. lucidum are triterpenes and polysaccharides. Triterpenes have hepatoprotective, antihypertensive, hypocholesterolemic, and antihistaminergic effects; polysaccharides (especially β-D-glucans) have antioxidant effects and protect cells from mutagenic damage.
Study Link
- ScienceDirect
Study data on dosage
In the largest placebo-controlled RCT to date (84 participants, 16 weeks), the researchers used 3 g Ganoderma lucidum daily (8 capsules, divided into 4 in the morning and 4 in the evening, with meals). This dosage was based on the literature recommendations available at the time.
Study Link
- PMC 4980683 / Scientific Reports RCT
In a safety study with 16 healthy volunteers, 2 g Reishi extract twice daily (= 4 g/day) administered over 10 days. No side effects were observed compared to the placebo group.
Study Link
- PubMed PMID 17597499
A GRADE-rated systematic review and meta-analysis (2025) examined clinical trials with Ganoderma doses of 200 to 11,200 mg/day over 1–24 weeks. Reishi showed significant reductions in BMI, creatinine, and heart rate. No significant effect was detected on blood pressure, blood lipids, or fasting glucose.
Study Link
- PMC 12160064
Reishi Dosage Table:
| Goal | Dose/Day | Dosage form | Study basis |
|---|---|---|---|
| Immunomodulation / general | 1000–1500 mg Extract | Capsules | PMID 17597499 |
| Cardiovascular risk factors | 3.000 mg | Capsules (4×2) | PMC 4980683 |
| Therapeutic (Cancer, Fatigue) | 3,000–5,400 mg | Spore powder | PMID 39241163 |
Sources / Preparations
Purchase criteria
- Only Fruiting body extract (no mycelium or mycelium on grain – very low active ingredient content!)
- Standardization Polysaccharide/Beta-Glucane ≥ 20–30 % and/or Triterpenes
- For cardiovascular/antioxidant effect: Dual extract (Water + Alcohol) are preferred because triterpenes are only soluble in alcohol
- Organic farming + heavy metal testing (mushrooms accumulate heavy metals!)
- PZN Number = Registered in Germany = Minimum Standard Met
Preparations
Bio Reishi Extract+Powder – Pestalozzi Pharmacy (Hawlik Vital Mushrooms)
- Combination of fruiting body extract + fruiting body powder
- Certified organic, rich in polysaccharides and beta-glucans
- Combined with organic acerola (natural vitamin C)
- Available at Pestalozzi Pharmacy and Bahnhof Pharmacy Kempten
Chiemsee Vital Mushrooms Organic Reishi Extract
- 30 % Polysaccharide (Beta-Glucan) guaranteed, fruiting body only
- Multiple pollutant tests (heavy metals, pesticides, mycotoxins)
- Shellbroken method for maximum bioavailability
Raab Vitalfood Organic Reishi Capsules
- Aqueous extract, controlled organic cultivation
- Combined with Acerola (Vitamin C) for synergistic effect
- Standardized polysaccharide concentration
- Available at many pharmacies and health food stores
Restriction For the vascular-stabilizing effect (triterpenes), a Dual extract required. Pure water extracts contain hardly any triterpenes. Hawlik offers dual extracts; please explicitly check for triterpenes in the product data sheet when purchasing.
Note: The Cochrane Review 2015 (PMID 25686270) found that Reishi for cardiovascular risk factors no proven clinical efficacy shows. Regarding blood vessel wall stabilization, Reishi remains the active ingredient with lowest clinical evidence of the four mentioned.
The extract type is crucial: for triterpenes (cardiovascularly relevant), a Dual extract (Water + Alcohol) present.
Maitake Mushroom (Grifola frondosa)
Active ingredients Polysaccharide (Beta-Glucan)
The Maitake mushroom supports healthy blood vessel function. Its potent polysaccharides strengthen the immune system and have antioxidant effects. VitaminFit
Silicic acid / Silicon (from horsetail, bamboo extract)
Silicic acid supports the formation of collagen and elastic fibers. VitaMoment Both are structural proteins that build up blood vessel walls and ensure their stability.
Sweet clover
Active ingredients Coumarin, Flavonoids
Sweet clover promotes lymphatic flow and has a decongestant effect Purazell – this supports microcirculation and relieves the vascular walls.
English Ivy (Hedera helix)
Herbal applications with ivy leaves can strengthen connective tissue. Dr. Gumpert – traditionally used as a compress or infusion.
Essential micronutrients as plant companions
| Fabric | Effect |
|---|---|
| vitamin C | Essential for collagen synthesis; synergistic with OPC |
| Flavonoids | Strengthens vein walls and valves Smarticular |
| Zinc | Collagen formation & wound healing |
| manganese | Key role in the formation of chondroitin sulfate, a central building block of connective tissue Purazell |
Vitamin C / Ascorbic acid (best understood at the molecular level)
Basic Mechanism - Collagen & Vascular Wall: Vitamin C is a cofactor for proline and lysine hydroxylases, which stabilize collagen types I and VI. Collagen type IV forms the main building block of vascular walls and basement membranes. A vitamin C deficiency inhibits collagen transcription in blood vessels through epigenetic DNA hypermethylation.
Study Link
- NCBI Bookshelf – StatPearls
Clinical Relevance – Capillary Bleeding: Acute vitamin C deficiency is characterized by microvascular complications such as widespread capillary hemorrhages. Ascorbate is required for the synthesis of collagen, the protein most critical for maintaining vascular integrity.
Study Link
- PubMed 8692035
Clinical Picture Scurvy: Hemorrhages are a typical characteristic of vitamin C deficiency: perifollicular hemorrhages, petechiae, ecchymoses, and coagulopathies can be attributed to the reduced integrity of connective tissue due to impaired collagen synthesis.
Study Link
- PMC 10296835
Recommended Daily Allowance (RDA) vs. Therapeutic Dose
The recommended daily intake (RDA) for adults is 75 mg/day for women and 90 mg/day for men. Smokers require an additional 35 mg/day due to increased oxidative stress. For the prevention of complex regional pain syndrome after wrist fracture, high-quality studies have shown 500 mg daily for 50 days used.
Study Link
- Journal of Orthopaedics – PDF
Vascular / Endothelial Effect
For optimal synthesis of collagen type IV (the main building block of the vascular basement membrane) by endothelial cells, intracellular ascorbate concentrations in the low millimolar range are required. In a clinical study in heart failure patients, an intravenous bolus of 2.5 g ascorbate, followed by 2 g/day for 3 days, reduced apoptotic endothelial microparticles to 32 % of baseline.
Study Link
- PMC 3869438 – Role of Vitamin C in the Vascular Endothelium
Study data on dosage
| Purpose | Dose/Day | Course foundation |
|---|---|---|
| RDA (Basic Supply) | 75–90 mg | Official Nutrition Societies |
| Collagen synthesis optimum oral | 200–500 mg | PMC 6204628 |
| Vascular endothelium / vascular effect | 500–1,000 mg | PMC 3869438 |
| Therapeutic for scurvy symptoms | 500–1,000 mg | PMID 36153722 |
| Synergy with OPC | Over 500 mg | Clinical experience (Morishige) |
Vitamin C is the strongest, cheapest, and safest Agents for vascular walls. When taken orally over 200 mg, the absorption rate decreases.
This is why liposomal vitamin C taken throughout the day (e.g., 2x 250 mg) is more efficient.
The Strongest herbal remedies specifically for porous blood vessels and hemorrhages based on current research, is it OPC (Grape Seed Extract / Pine Bark Extract) in Combination with natural Vitamin C.
German
Afrikaans
Chinese
Czech
Danish
Dutch
English
Finnish
French
Greek
Hungarian
Italian
Japanese
Latvian
Lithuanian
Norwegian
Portuguese
Slovak
Slovenian
Spanish
Swedish
Russian
Turkish